AbbVie’s hotly anticipated psoriasis drug Skyrizi (risankizumab) has been approved in Japan, the first country to okay this potential blockbuster. Skyrizi is important for AbbVie as sales of its ...

Crohn's the third indication for Skyrizi after psoriasis and psoriatic arthritis, and a key step in AbbVie's aim to grow the drug – already one of its top sellers with sales of almost $3 billion ...

Skyrizi had an estimated national TV ad spend of $367.7 million — the highest ad spend of any brand in the top 10.

Study highlights the efficacy and safety of tildrakizumab in improving physical, psychological, and social aspects of quality ...

Lilly already sells several treatments for inflammatory conditions like arthritis and psoriasis ... in combining its ...

The efficacy and safety of a proposed biosimilar and ustekinumab are similar among adults with moderate to severe plaque psoriasis.

Even after a flurry of corporate updates during the first two days of the J.P. Morgan Healthcare Conference, many more ...